Last reviewed · How we verify

Vascular headache — Treatment Landscape & Competitive Intelligence

Vascular headache (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Vascular headache, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Norgesic caffeine Hikma Central Nervous System Stimulant [EPC] Adenosine receptor A2a 1948-01-01
Migranal DIHYDROERGOTAMINE Bausch Health Ergotamine Derivative D(3) dopamine receptor 1946-01-01
Ergot Ergot Samuel Lunenfeld Research Institute, Mount Sinai Hospital 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
phenobarbitone phenobarbitone Institute of Child Health Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Vascular headache
  2. Bausch Health · 1 drug in Vascular headache
  3. Hikma · 1 drug in Vascular headache
  4. Institute of Child Health · 1 drug in Vascular headache
  5. Samuel Lunenfeld Research Institute, Mount Sinai Hospital · 1 drug in Vascular headache

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Vascular headache:

Cite this brief

Drug Landscape (2026). Vascular headache — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/vascular-headache. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing